Patents by Inventor Wei-I Chou
Wei-I Chou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10172931Abstract: A recombinant baculovirus displaying on its envelop a fusion protein is disclosed. The fusion protein comprises a heterologous antigen, and a C-terminal region of baculovirus envelope GP64 protein, which has at least 100 amino acid residues in length and lacks a B12D5 binding epitope located within the central basic region of the GP64 protein. The genome of the recombinant baculovirus comprises a transgene encoding a fusion protein that comprises a signal peptide, the heterologous antigen, and the C-terminal region of the baculovirus envelope GP64 protein, in which the antigen is located between the signal peptide and the C-terminal region of the GP64 protein. Methods for eliciting an antigen-specific immunogenic response in a subject in need thereof are also disclosed.Type: GrantFiled: May 13, 2016Date of Patent: January 8, 2019Assignee: REBER GENETICS CO., LTD.Inventors: Chia-Jung Chang, Yan-Chiou Liao, Wei-I Chou, Hsiu-Kang Chang
-
Patent number: 10010602Abstract: A fusion protein comprising an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a translocation peptide, a fusion antigen, an endoplasmic reticulum retention sequence, and optionally a nuclear export signal is disclosed. The fusion antigen comprises a porcine reproductive and respiratory syndrome virus (PRRSV) ORF7 antigen, a PRRSV ORF1b antigen, a PRRSV ORF6 antigen, and a PRRSV ORF5 antigen. The fusion protein is useful for inducing antigen-specific cell-mediated and humoral responses.Type: GrantFiled: May 27, 2016Date of Patent: July 3, 2018Assignee: REBER GENETICS CO., LTD.Inventors: Yu-Hsin Chien, Meng-Ju Tsai, Pao-Yen Lai, Wei-I Chou, Hsiu-Kang Chang
-
Patent number: 9676826Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: GrantFiled: April 13, 2016Date of Patent: June 13, 2017Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I Chou, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Publication number: 20160346377Abstract: A fusion protein comprising an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a translocation peptide, a fusion antigen, an endoplasmic reticulum retention sequence, and optionally a nuclear export signal is disclosed. The fusion antigen comprises a porcine reproductive and respiratory syndrome virus (PRRSV) ORF7 antigen, a PRRSV ORF1b antigen, a PRRSV ORF6 antigen, and a PRRSV ORF5 antigen. The fusion protein is useful for inducing antigen-specific cell-mediated and humoral responses.Type: ApplicationFiled: May 27, 2016Publication date: December 1, 2016Inventors: Yu-Hsin CHIEN, Meng-Ju TSAI, Pao-Yen LAI, Wei-I CHOU, Hsiu-Kang CHANG
-
Publication number: 20160331826Abstract: A recombinant baculovirus displaying on its envelop a fusion protein is disclosed. The fusion protein comprises a heterologous antigen, and a C-terminal region of baculovirus envelope GP64 protein, which has at least 100 amino acid residues in length and lacks a B12D5 binding epitope located within the central basic region of the GP64 protein. The genome of the recombinant baculovirus comprises a transgene encoding a fusion protein that comprises a signal peptide, the heterologous antigen, and the C-terminal region of the baculovirus envelope GP64 protein, in which the antigen is located between the signal peptide and the C-terminal region of the GP64 protein. Methods for eliciting an antigen-specific immunogenic response in a subject in need thereof are also disclosed.Type: ApplicationFiled: May 13, 2016Publication date: November 17, 2016Inventors: Chia-Jung CHANG, Yan-Chiou LIAO, Wei-I CHOU, Hsiu-Kang CHANG
-
Publication number: 20160229896Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: ApplicationFiled: April 13, 2016Publication date: August 11, 2016Inventors: WEI-I CHOU, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Patent number: 9339536Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: GrantFiled: December 3, 2013Date of Patent: May 17, 2016Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I Chou, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Patent number: 8999688Abstract: A polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X1NNNX2X3NYQX4X5X6X7X8, wherein the X1 and X8 mean a pair of opposite charged amino acid residues, and the X2, X3, X4, X5, X6, or X7 means an amino acid residue is described. A mixture for diminishing a polysaccharide, comprising at least two starch binding domains (SBDs) and a polysaccharide in a helix form is also presented. A method of providing an oligosaccharide, and a method of producing an amyloid-like fibril and use thereof are further described.Type: GrantFiled: January 19, 2011Date of Patent: April 7, 2015Assignee: National Tsing Hua UniversityInventors: Margaret Dah-Tsyr Chang, Yuh-Ju Sun, Ping-Chiang Lyu, Shu-Chuan Lin, Wei-I Chou
-
Publication number: 20140154280Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: ApplicationFiled: December 3, 2013Publication date: June 5, 2014Applicant: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I CHOU, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Patent number: 8372951Abstract: A cell penetrating peptide which has following sequence: NYBX1BX2BNQX3, wherein B represents a basic amino acid, X1 represents an amino acid with an aromatic, a hydrophobic or an uncharged side chain, X2 represents any amino acid, and X3 represents N or none is described. A method for delivering a cargo into a subject by administrating a complex comprising the cell penetrating peptide and the desired cargo to the subject is also described.Type: GrantFiled: May 14, 2010Date of Patent: February 12, 2013Assignee: National Tsing Hua UniversityInventors: Margaret Dah-Tsyr Chang, Shun-Lung Fang, Wei-I Chou, Shu-Chuan Lin
-
Patent number: 8293465Abstract: The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.Type: GrantFiled: April 6, 2010Date of Patent: October 23, 2012Assignee: National Tsing Hua UniversityInventors: Margaret Dah-Tsyr Chang, Yuan-Chuan Lee, Rong-Yuan Huang, Shu-Chuan Lin, Wei-I Chou, Shi-Hwei Liu
-
Publication number: 20110280798Abstract: The present invention provides a cell penetrating peptide which has following sequence: NYBX1BX2BNQX3, wherein B represents a basic amino acid, X1 represents an amino acid with an aromatic, a hydrophobic or an uncharged side chain, X2 represents any amino acid, and X3 represents N or none. The present invention also provides a method for delivering a cargo into a subject by administrating a complex comprising the cell penetrating peptide and the desired cargo to the subject.Type: ApplicationFiled: May 14, 2010Publication date: November 17, 2011Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Margaret Dah-Tsyr Chang, Shun-Lung Fang, Wei-I Chou, Shu-Chuan Lin
-
Publication number: 20110129853Abstract: A polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X1NNNX2X3NYQX4X5X6X7X8, wherein the X1 and X8 mean a pair of opposite charged amino acid residues, and the X2, X3, X4, X5, X6, or X7 means an amino acid residue is described. A mixture for diminising a polysaccharide, comprising at least two starch binding domains (SBDs) and a polysaccharide in a helix form is also presented. A method of providing an oligosaccharide, and a method of producing an amyloid-like fibril and use thereof are further described.Type: ApplicationFiled: January 19, 2011Publication date: June 2, 2011Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Margaret Dah-Tsyr Chang, Yuh-Ju Sun, Ping-Chiang Lyu, Shu-Chuan Lin, Wei-I Chou
-
Patent number: 7919580Abstract: A polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X1NNNX2X3NYQX4X5X6X7X8, wherein the X1 and X8 mean a pair of opposite charged amino acid residues, and the X2, X3, X4, X5, X6, or X7 means an amino acid residue is described. A mixture for diminising a polysaccharide, comprising at least two starch binding domains (SBDs) and a polysaccharide in a helix form is also presented. A method of providing an oligosaccharide, and a method of producing an amyloid-like fibril and use thereof are further described.Type: GrantFiled: January 23, 2009Date of Patent: April 5, 2011Assignee: National Tsing Hua UniversityInventors: Margaret Dah-Tsyr Chang, Yuh-Ju Sun, Ping-Chiang Lyu, Shu-Chuan Lin, Wei-I Chou
-
Publication number: 20100291601Abstract: The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.Type: ApplicationFiled: April 6, 2010Publication date: November 18, 2010Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Margaret Dah-Tsyr Chang, Yuan-Chuan Lee, Rong-Yuan Huang, Shu-Chuan Lin, Wei-I Chou, Shi-Hwei Liu
-
Publication number: 20100291540Abstract: The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.Type: ApplicationFiled: May 12, 2009Publication date: November 18, 2010Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Margaret Dah-Tsyr Chang, Yuan-Chuan Lee, Rong-Yuan Huang, Shu-Chuan Lin, Wei-I Chou, Shi-Hwei Liu
-
Publication number: 20090186369Abstract: The present invention relates to a polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X1NNNX2X3NYQX4X5X6X7X8, wherein the X1 and X8 mean a pair of opposite charged amino acid residues, and the X2, X3, X4, X5, X6, or X7 means an amino acid residue. The present invention also relates to a mixture for diminising a polysaccharide, comprising at least two starch binding domains (SBDs) and a polysaccharide in a helix form. The present invention further relates to a method of providing an oligosaccharide, and a method of producing an amyloid-like fibril and use thereof.Type: ApplicationFiled: January 23, 2009Publication date: July 23, 2009Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Margaret Dah-Tsyr Chang, Yuh-Ju Sun, Ping-Chiang Lyu, Shu-Chuan Lin, Wei-I Chou